Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.

Luigi D'AntonioCristiano FieniStefania Livia CiummoSimone VespaLavinia LottiCarlo SorrentinoEmma Di Carlo

Published in: Journal for immunotherapy of cancer (2023)

IL30 is a new CRC driver, since its inactivation, which disables oncogenic pathways and multiple autocrine loops, inhibits CR-CSC tumorigenicity and metastatic ability. The development of CRISPR/Cas9-mediated targeting of IL30 could improve the current therapeutic landscape of CRC.

Keyphrases

crispr cas
genome editing
stem cells
small cell lung cancer
transcription factor
single cell
cell therapy
free survival